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Background: Mannose binding lectin (MBL) is a key mediator of both innate immunity and efferocytosis 
(phagocytosis of apoptotic cells) in the airway. Defective efferocytosis results in a net increase in 
apoptotic material that can undergo secondary necrosis, leading to tissue damage and chronic 
inflammation. We have shown reduced MBL and efferocytosis in other chronic inflammatory lung 
diseases; we therefore hypothesized that reduced MBL and efferocytosis in the airways may be a 
determinant of bronchiolitis obliterans syndrome (BOS) following lung transplantation. Methods: We 
investigated MBL (ELISA), MBL-mediated complement deposition (UC4, ELISA) and efferocytosis of 
apoptotic bronchial epithelial cells (flow cytometry) in bronchoalveolar lavage (BAL) and peripheral 
blood from 75 lung transplant recipients (16 with stable graft function, 34 stable with proven infection, 25 
with BOS) and 14 healthy controls.  
Abstract & Manuscript
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Results: In plasma, MBL levels were highly variable (0-17.538 g/mL), but increased in infected subjects 
vs control (p=0.09) or stable groups (p=0.003). There was a similar increase in UC4 in infected patients 
and a significant correlation between MBL and UC4. There was no correlation between MBL and time 
post-transplant. In BAL, MBL levels were less variable (0-73.3 ng/mL) and significantly reduced in 
patients with BOS vs controls and stable groups. Efferocytosis was significantly reduced in the BOS 
group vs control and stable groups (Mean [SEM] Control: 20% [1.3%], Stable 20.5% [2.5%], Infected 
17.3% [2.8%], BOS 11.3% [1.5%, p=.04]).  
Conclusions: Low levels of MBL in the airway may play a role in reduced efferocytosis, subsequent 
tissue damage and BOS following lung transplantation.  
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Lung transplantation is now recognized as an effective treatment option for a variety of end-stage lung 
diseases and is associated with improvements in life expectancy and quality of life. However the five-year 
survival is currently only around 60%, the worst of any solid organ transplant, with death beyond the acute 
phase being largely due to progressive and treatment refractory airway remodeling (obliterative 
bronchiolitis, OB) manifest clinically as bronchiolitis obliterans syndrome (BOS). BOS is thought to 
follow persistent alloreactive, infective, and non-specific epithelial injury with dysregulated epithelial 
repair
1
. Although the predominant histopathologic finding in patients with OB is of fibro-proliferative 
small airway obliteration, large airways are also affected with the eventual development of bronchiectasis, 
leading directly to patient morbidity and mortality.  
The well-ordered process of apoptosis is important for regulation and maintenance of normal tissue 
homeostasis. During resolution of airway inflammation, apoptotic epithelial cells are removed by 
phagocytosis by alveolar macrophages (a process termed ‘efferocytosis’). The pathological concept of 





 chronic granulomatous disease 
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It is considered that the failed efferocytosis results in a net increase in apoptotic material that may lead to 
secondary necrosis of this material resulting in increased tissue damage and chronic inflammation. This 
was clearly shown in our studies of COPD where we found evidence of secondary necrosis (increased 
lactate dehydrogenase in BAL) and that the increased numbers of apoptotic bronchial epithelial cells 
negatively correlated with efferocytosis
6,9
. In lung transplant recipients we have also described an 
accumulation of apoptotic material associated with an increase in the cytotoxic mediator granzyme b in 
the airways 
10,11
.   
Mannose binding lectin (MBL) is a key mediator of both innate immunity and efferocytosis and is thus 
likely to be important in protecting against lung tissue damage. In other inflammatory chronic lung 
diseases including COPD, we have shown reduced levels of MBL that correlated with a defect in the 
 4 
ability of alveolar macrophages to phagocytose apoptotic bronchial epithelial cells (efferocytosis)
8
. We 
further showed that treatment of smoking mice (which replicate the inflammation and macrophage 
dysfunction found in our human subjects) with plasma-derived MBL improved efferocytosis by both 




We therefore hypothesized there would be decreased efferocytosis associated with low levels of MBL in 
the airways of patients with BOS.  It is probable that these deficiencies would significantly contribute to 
increased numbers of uncleared apoptotic cells and secondary necrosis with tissue damage and an 
abnormal inflammatory response leading to in OB following lung transplantation. Importantly, this 
pathway may provide new treatment options for BOS, an area of major unmet clinical need. Our lung 
transplant patients undergo frequent bronchoscopic evaluation, either in the context of surveillance to 
detect pre-clinical histological signs of rejection or in the context of acute deteriorations where samples 
are required for a specific diagnosis. These have provided an ideal opportunity to evaluate the role of 
efferocytosis and key mediators in both stable subjects and those with infection, acute rejection or BOS. 
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Materials and Methods 
Subjects  
Subjects were recruited from the South Australian Lung Transplant Service. Rejection status was 
categorized both clinically and histologically on transbronchial biopsies according to standard criteria. 
Pathologists were blinded to the results of flow cytometric testing. Patients were maintained on standard 
immunosuppressive therapy (Cyclosporin A or Tacrolimus, mycophenolate or azathioprine and 
prednisolone). Bronchoalveolar lavage (BAL) and peripheral blood (collected into lithium heparin) was 
obtained from lung transplant recipients with (a) stable graft function (blood from n=16; BAL from n=10), 
(b) BOS (blood n=25; BAL n=11) (c) stable function with infection (blood n=34; BAL n=10) and d) 
normal controls (never-smokers with no history of respiratory or allergic disease and normal spirometry) 
(blood and BAL, n=14). All groups were age-matched as closely as possible. Patient demographics are 
presented in Table 1. 
Flexible bronchoscopy 
Bronchoscopy was performed according to expert consensus recommendations for the performance of 
bronchoscopy for investigative purposes (American Thoracic Society) and as previously reported by us
5-8
. 
Briefly, BAL was collected after wedging the bronchoscope tip into a subsegmental airway. A 50mL 
aliquot of sterile normal saline (at room temperature) was instilled with a syringe then aspirated using low 
suction into a 50mL plastic suction trap. Two further aliquots of saline were instilled and aspirated in the 
same way into two further traps. The first aliquot was not used for analysis due to bronchial contamination 
but processed for microbiological testing. Aspirated BAL was immediately transferred to 50mL 
polypropylene tubes (to avoid attachment of cells to the polystyrene plastic trap) and kept on ice.  
Preparation of BAL  
BAL was prepared and alveolar macrophages were isolated from BAL by adhering to plastic as previously 
reported
5




Measurement of soluble MBL  
MBL levels were determined in batches of undiluted frozen BAL and plasma samples using commercial 
ELISA kits (HyCult Biotechnology, Uden, The Netherlands) following instructions supplied by the 
manufacturer. The lower limit of detection was 0.41 ng/mL. 
Complement activation assay 
C4 deposition was measured using ELISA as previously described
13 
which arbitrarily quantifies C4 
deposited onto a solid phase mannan surface. After MBL binding to mannan, subsequent C4 deposition 
was measured using a biotinylated anti-C4 antibody (Sigma-Aldrich, Castle Hill, NSW, Australia). 1mL 
of Statens Serum Institue Standard (Statens, Denmark) was arbitrarily assigned 1000U C4 deposition. 
MBL-mediated C4 deposition was measured in UC4/l. samples.   
Efferocytosis of apoptotic bronchial epithelial cells by alveolar macrophages 
A flow-cytometric efferocytosis assay was performed using alveolar macrophages from BAL as 
previously reported
5,14
. Briefly immortalized normal bronchial epithelial cells (16HBE) were induced to 
undergo apoptosis using UV radiation for 20 min then stained with mitotracker red (MTR) (50L, 
25g/mL) and used as phagocytic targets. One mL aliquots of alveolar macrophages (4x105/mL) in culture 
medium were adhered to 24 well culture plates for 2h, then fluid removed and 1mL apoptotic cells 
(4x10
6
/mL) added for 1.5h.  
Statistical analysis 
We used the Shapiro-Wilk test for normality, ANOVA plus post hoc t-test or Kruskal Wallis plus post hoc 
Mann Whitney as relevant. Correlations were performed using Pearson Correlation Coefficients, 
significance p<0.05  
Results 
Measurement of MBL  
 7 
In plasma, MBL levels were highly variable (0-17.538 g/mL). No significant differences were noted 
among the transplant groups vs non-transplant controls, although there was a trend (p=0.099) for increased 
MBL in the infection group vs controls (Figure 1A). There was a significant (p=0.003) increase in MBL in 
the infection group vs stable transplant patients (Figure 1A). Notably, in plasma, 34% transplant patients 
with stable graft function (7/16) or BOS (7/25) met the accepted definition of MBL deficiency (less than 
0.1g/mL)12, whereas only 1/34 with infection and two of the 14 control subjects were MBL deficient.  
In BAL, MBL levels were lower than in plasma but less variable (range 0-74 ng/mL) and significantly 
reduced in patients with BOS vs healthy controls and transplant patients with stable graft function. There 
were no significant differences in MBL in BAL from any other transplant group (MBL ng/mL: (mean ± 
SEM) Controls: 6.2 ± 1; stable 8.6 ± 3.8; stable infected 10.7 ± 2.7; BOS 2.2 ± 1.7) (Figure 2). There was 
no significant correlation between plasma and BAL levels of MBL (Pearson correlation 0.168, p=0.263).   
Complement activation assay 
In BAL, values were below the lower limits of detection for the assay. In plasma, values ranged from 
0.013 to 0.634 UC4/uL, and no significant differences were noted between non-transplant controls and 
transplant groups (Figure 1B) There was a significant (p=0.003) increase in MBL mediated C4 deposition 
in the infection groups vs stable transplant patients (p=0.037) and a trend for an increase in the BOS vs 
stable groups (p=0.096) (Figure 1B). 
There was a significant correlation between MBL levels in plasma and UC4/uL (Pearson correlation 
0.805; p=<0.001) (Figure 1C). 
Efferocytosis of apoptotic bronchial epithelial cells by alveolar macrophages 
Alveolar macrophages from patients with BOS had significantly reduced ability to efferocytose apoptotic 
airway epithelial cells compared to patients with stable graft function. Investigations of the further group 
of stable patients with infection showed alveolar macrophage phagocytic ability that was not significantly 
decreased vs the ‘stable’ group (Figure 3). 
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Correlations between MBL, efferocytosis and time post-transplant 
Consistent with our previous findings of a significant correlation between MBL and efferocytosis in 
patients with COPD
8
, the present study noted a trend for correlation between alveolar macrophage 
efferocytosis ability and MBL levels in BAL (Pearson correlation 0.399, p=0.090, n=25). There was no 
significant correlations between MBL and time post-transplant or pre-transplant diagnosis (Pearson 
correlation -0.204; p=0.115).  
Discussion 
Current diagnosis of OB is difficult; histopathology assessment is notoriously unreliable
15
 and physiologic 
techniques are insensitive to early changes in resistance in the small airway, so that by the time a clinical 
diagnosis of BOS is made, a substantial proportion of airways may have been irretrievably obliterated. 
Therapeutic intervention is likely to be more effective if applied earlier; therefore, a more complete 
understanding of the pathogenesis of BOS is urgently required to enable and identify new treatment 
targets. 
The processes leading up to BOS are incompletely understood but are thought to include persistent 
alloreactive, infective, and non-specific epithelial injury with dysregulated epithelial repair
1
. These 
processes culminate in remodeling and fibrotic obstruction of the small airways. The initiators of these 
changes are most likely multi-factorial, and we have shown that T-cells from patients with BOS have 
increased levels of pro-inflammatory cytokines and granzymes associated with graft rejection, epithelial 
cell death and the process of epithelial mesenchymal transition
11,16,17
. We have further shown increased 
numbers of apoptotic bronchial epithelial cells in the airways of lung transplant recipients and suggested 
that secondary necrosis of the uncleared apoptotic material could contribute to the perpetuation of chronic 
inflammation and tissue damage that precedes BOS
10
.  
The present study extended these observations to show that the increased number of apoptotic cells in the 
airway in BOS may result from a defective ability of alveolar macrophages to phagocytose these cells 
(efferocytosis), associated with low levels of MBL (required for effective efferocytosis).  The changes 
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were not related to time post-transplant. The relevance of uncleared apoptotic cells in subsequent 
development of fibrosis has been highlighted by several studies including a comprehensive review by PM 
Henson in 2003
2
.  One potential consequence of these accumulated cells may be high levels of the pro-
fibrotic cytokine TGF-β (produced by macrophages ingesting the apoptotic cells) that may contribute to 
the pulmonary fibrosis in BOS
2
. 
Although traditionally recognized as a mediator of host defense by its ability to facilitate macrophage 
phagocytosis of pathogens, MBL is now recognized to regulate the clearance of apoptotic cells
18,19
, by a 
process that involves recognition of mannose containing pathogen associated molecular patterns (PAMPs) 
and ‘altered self’ involved in the macrophage-target cell interaction18. As such, the reduced levels of MBL 
noted in BOS may provide an environment which promotes the significant defect in efferocytosis of 
apoptotic cells and progression to airway obliteration in OB. Low plasma levels of MBL are associated 
with increased susceptibility to infection, and poorer prognosis in cystic fibrosis
20,21
. The association of 
low MBL in plasma from both donor and recipient with susceptibility to infection has also been well-
described in a variety of transplant settings including liver, renal, kidney-pancreas and heart
22-24
. The low 
MBL levels were, in most cases, associated with MBL gene polymorphisms
25-27
.  
Despite these numerous studies of MBL in plasma, there have been no studies investigating the role of 
MBL in the airway or with regard to efferocytosis of apoptotic cells and the link to tissue damage, 
inflammation and progression to BOS in lung transplant patients. The present study found differences in 
MBL levels in plasma and airway. Significantly reduced levels of MBL were noted in the airway of 
patients with BOS vs non-transplant controls or stable lung transplant patients whereas, in the blood, 
levels were highly variable and no difference was found between the transplant groups. This is consistent 
with previous studies by our group and others that have shown that plasma levels of MBL are highly 
variable, thought to be due to the genetic polymorphisms complicating correlation with disease 
processes
12,26
.   
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Although we found no evidence from peripheral blood for a difference in the ability of transplant patients 
and controls to activate complement in response to MBL binding to solid phase mannose moieties,  we 
were not able to assess complement activation in the airway, as levels were below the limits of detection 
in BAL. Complement binds directly and specifically to surface blebs of apoptotic cells including vascular 
endothelial cells
27-29
; it is therefore probable that the uncleared apoptotic cells that remain as a result of the 
defective efferocytosis in OB have the potential to directly activate complement and contribute to 
complement mediated tissue injury.  It is also possible that even low levels of MBL in BAL from patients 
with BOS are still sufficient to activate complement and mediate an effect on C4 deposition in the airway, 
but not sufficient to exert the essential pro-efferocytosis effects on alveolar macrophages. This is 
supported by a previous report that showed that increased complement activation despite low levels of 
plasma MBL contributed to graft rejection following heart transplantation
22
. It is also likely that MBL may 
exert its effects differentially in the peripheral and lung compartments; a ‘double edged sword effect’.  
This may be due to the unique ability of alveolar macrophages to retain very high concentrations of certain 
mediators (eg, macrolide antibiotics) when compared to plasma concentrations
30
.  
These findings have direct implication for potential adjunct treatment for BOS and provide a rationale for 
investigating MBL as a therapy in this disease. MBL has been successfully administered by an intra-nasal 
route for treatment of murine model of invasive pulmonary aspergillosis
31
. In humans, plasma-derived 
MBL has been applied in a phase I human study in MBL-deficient healthy male subjects, establishing the 
safety of the approach
32
. A second generation nonofiltered plasma-derived MBL has been developed by 
Statens Serum Institute, Denmark, and has now successfully undergone phase II human studies
33,34
. 
Consistent with this evidence we have previously demonstrated that we could improve efferocytosis and 
reduce inflammation by treating mice that had a smoke-induced MBL and efferocytosis deficiency with 
aerosolized plasma derived MBL
11
.  
Data from this study strongly implicate the MBL pathway in the defective macrophage efferocytosis 
function in OB, and suggest that modulation of efferocytosis in the airway using MBL therapy may be a 
 11 
useful adjunct therapeutic strategy to prevent the progression of BOS following lung transplantation. 
Intra-nasal or aerosolized administration of MBL would be an attractive treatment option for these patients.  
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Table 1. Demographic details of study subjects. Data presented as Mean ± SEM. Tx: Transplant, FEV1: 



















Figure 1. A. Levels of MBL and B. complement activation (UC4/L) in plasma from healthy controls 
(Control), lung transplant recipients with stable graft function (Stable), stable graft function +infection 
(Infect) or bronchiolitis obliterans syndrome (BOS) *significant p<0.05 increase vs Control or Stable. C. 




































































Figure 2. MBL was determined by ELISA in BAL from healthy controls, lung transplant patients with 
stable graft function (Stable), patients with stable graft function but proven infection (Infect) and those 



































Figure 3. Efferocytosis of apoptotic bronchial epithelial cells by alveolar macrophages obtained from 
bronchoalveolar lavage from never-smoker controls, lung transplant patients with stable graft function 
(Stable), patients undergoing an acute rejection episode (Acute rejection), patients with stable graft 
function but proven infection (Infection) and those with bronchiolitis obliterans syndrome (BOS). 
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Figure 1. A. Levels of MBL and B. complement activation (UC4/L) in plasma from healthy 
controls (Control), lung transplant recipients with stable graft function (Stable), stable graft 
function +infection (Infect) or bronchiolitis obliterans syndrome (BOS) *significant p<0.05 
increase vs Control or Stable. C. Significant correlation between plasma MBL levels and 
complement activation (Pearson correlation 0.805; p=<0.001). 
Figure 2. MBL was determined by ELISA in BAL from healthy controls, lung transplant patients 
with stable graft function (Stable), patients with stable graft function but proven infection (Infect) 
and those with bronchiolitis obliterans syndrome (BOS). *significant (p<0.05) decrease ‘BOS’ vs 
‘Controls’ or ‘Stable’ groups. 
Figure 3. Efferocytosis of apoptotic bronchial epithelial cells by alveolar macrophages obtained 
from bronchoalveolar lavage from never-smoker controls, lung transplant patients with stable 
graft function (Stable), patients undergoing an acute rejection episode (Acute rejection), patients 
with stable graft function but proven infection (Infection) and those with bronchiolitis obliterans 
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Figure 2. MBL was determined by ELISA in BAL from healthy controls, lung transplant patients 
with stable graft function (Stable), patients with stable graft function but proven infection (Infect) 
and those with bronchiolitis obliterans syndrome (BOS). *significant (p<0.05) decrease ‘BOS’ vs 

































Figure 3. Efferocytosis of apoptotic bronchial epithelial cells by alveolar macrophages obtained 
from bronchoalveolar lavage from never-smoker controls, lung transplant patients with stable 
graft function (Stable), patients undergoing an acute rejection episode (Acute rejection), patients 
with stable graft function but proven infection (Infection) and those with bronchiolitis obliterans 
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